Evidence map›Paper›PMID 35212939›Full record

ArticleMolecular neurobiology2022

Novel Exosome Biomarker Candidates for Alzheimer's Disease Unravelled Through Mass Spectrometry Analysis.

Tânia Soares Martins, Rui Marçalo, Cristóvão B da Cruz E Silva, Dário Trindade, José Catita, Francisco Amado, Tânia Melo, Ilka Martins Rosa, Jonathan Vogelgsang, Jens Wiltfang and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular neurobiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Tânia Soares MartinsNeuroscience and Signalling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro (UA), 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0003-3017-2092
Rui MarçaloNeuroscience and Signalling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro (UA), 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0003-0699-335X
Cristóvão B da Cruz E SilvaLaboratory of Instrumentation and Experimental Particle Physics-LIP, Av. Elias Garcia 14-1º, 1000-149, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-1231-3819
Dário TrindadeNeuroscience and Signalling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro (UA), 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0002-8536-4609
José CatitaCEBIMED-Faculty of Health Sciences, University Fernando Pessoa, 4249-004, Porto, Portugal.ORCID http://orcid.org/0000-0001-7270-5702
Francisco AmadoDepartment of Chemistry, QOPNA (Organic Chemistry Natural and Agrofood Products and LAVQ REQUIMTE), University of Aveiro, 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0001-8256-1749
Tânia MeloDepartment of Chemistry, QOPNA (Organic Chemistry Natural and Agrofood Products and LAVQ REQUIMTE), University of Aveiro, 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0002-0508-4034
Ilka Martins RosaNeuroscience and Signalling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro (UA), 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0001-6536-8728
Jonathan VogelgsangDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Georg-August University, Von-Siebold-Str. 5, 37075, Goettingen, Germany.ORCID http://orcid.org/0000-0001-9326-8193
Jens WiltfangNeuroscience and Signalling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro (UA), 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0003-1492-5330
Odete A B da Cruz E SilvaNeuroscience and Signalling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro (UA), 3810-193, Aveiro, Portugal.ORCID http://orcid.org/0000-0003-3718-9874
Ana Gabriela HenriquesNeuroscience and Signalling Group, Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro (UA), 3810-193, Aveiro, Portugal. aghenriques@ua.pt.ORCID http://orcid.org/0000-0003-0851-6979
University of Aveiro · PTRede de Química e Tecnologia · PTFernando Pessoa University · PTGerman Center for Neurodegenerative Diseases · DELIP - Laboratory of Instrumentation and Experimental Particle Physics · PTMcLean Hospital · US

Funding

Alzheimer's Association 2019-AARG-644347Fundação para a Ciência e a Tecnologia SFRH/BD/145979/2019 (Ph.D. scholarship)
6 · The paper itself

Abstract

Exosomes are small extracellular vesicles (EVs) present in human biofluids that can transport specific disease-associated molecules. Consequently blood-derived exosomes have emerged as important peripheral biomarker sources for a wide range of diseases, among them Alzheimer's disease (AD). Although there is no effective cure for AD, an accurate diagnosis, relying on easily accessible peripheral biofluids, is still necessary to discriminate this disease from other dementias, test potential therapies and even monitor rate of disease progression. The ultimate goal is to produce a cost-effective and widely available alternative, which can also be employed as a first clinical screen. In this study, EVs with exosome-like characteristics were isolated from serum of Controls and AD cases through precipitation- and column-based methods, followed by mass spectrometry analysis. The resulting proteomes were characterized by Gene Ontology (GO) and multivariate analyses. Although GO terms were similar for exosomes' proteomes of Controls and ADs, using both methodologies, a clear segregation of disease cases was obtained when using the precipitation-based method. Nine significantly different abundant proteins were identified between Controls and AD cases, representing putative biomarker candidate targets. Among them are AACT and C4BPα, two Aβ-binding proteins, whose exosome levels were further validated in individuals from independent cohorts using antibody-based approaches. The findings discussed represent an important contribution to the identification of novel exosomal biomarker candidates useful as potential blood-based tools for AD diagnosis.

Indexed as

Alzheimer DiseaseExosomesBiomarkersHumansMass SpectrometryProteomeBiomarkersProteomeAlzheimer’s diseaseBiomarkersBloodDiagnosisExosomesExtracellular vesicles

Identifiers

PMID35212939
PMCPMC9016047
OpenAlexW4214573479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.